Cyril Lucien Bouland, Rokneddine Javadian, Sarah Gilis, Antoine Yanni, Maxime Le Clercq, Pierre Mestrallet, Stelianos Kampouridis, Dominique Bron, Martin Lalmand, Xavier Vanden Eynden, Edward Boutremans, Didier Dequanter, Isabelle Loeb, Pierre Philippart, Laurence Lagneaux, Nathalie Meuleman
Introduction: Medication-related osteonecrosis of the jaw (MRONJ) poses a significant challenge considering the absence of a "gold standard" treatment. Cell-based therapy and tissue engineering offer promising therapeutic alternatives. This study aimed to harness the regenerative properties of adipose-tissue stromal vascular fraction (AT-SVF) and leukocyte-platelet-rich fibrin (L-PRF) for MRONJ treatment. AT-SVF contains mesenchymal stromal cells (MSC) and endothelial progenitor cells (EPC), which promote bone formation, while the L-PRF scaffold can serve as a three-dimensional scaffold for the AT-SVF and support tissue healing through growth factor release...
2024: Frontiers in Cell and Developmental Biology